ANKRD62: A Potential Drug Target and Biomarker (G342850)

Target Name: ANKRD62

NCBI ID: G342850

ANKRD62

Other Name(s): DKFZp779B1634 | ankyrin repeat domain 62 | ANR62_HUMAN | Ankyrin repeat domain-containing protein 62 | Ankyrin repeat domain 62

ANKRD62: A Potential Drug Target and Biomarker

Ankyrin A protein, also known as ANKRD62, is a member of the ANKRIN gene family and is expressed in various tissues and organs, including brain, heart, and muscle. It has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

The ANKRIN gene is located on chromosome 1p36 and encodes a 21-kDa protein that is involved in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. The ANKRIN protein has been shown to play a role in regulating gene expression and has been implicated in the development and progression of various diseases.

One of the most promising aspects of ANKRIN is its potential as a drug target. The use of ANKRIN as a drug target is based on the idea that manipulating the activity of ANKRIN can have therapeutic effects on diseases that are caused by the disruption of normal cellular processes.

Ankyrin has been shown to interact with various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many drugs that are used to treat diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The ANKRIN protein has been shown to play a negative role in the TGF-β pathway and has been shown to inhibit the activity of the transcription factor, SMAD, which is a key player in the TGF-β pathway. This means that when ANKRIN is expressed at high levels, it can inhibit the activity of SMAD, which can lead to the disruption of normal cellular processes and the development of diseases.

In addition to its potential as a drug target, ANKRIN has also been identified as a potential biomarker for several diseases. The ANKRIN protein is expressed in various tissues and organs and has been shown to be involved in the development and progression of several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the most promising aspects of ANKRIN as a biomarker is its potential to be used as a diagnostic tool for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and are typically treated with neuroprotective drugs that aim to slow down or halt the progression of the disease.

Ankyrin has been shown to be involved in the development and progression of neurodegenerative disorders and has been shown to interact with the neurotransmitter, 尾-amyloid, which is a hallmark of Alzheimer's disease. Studies have shown that the level of 尾-amyloid in the brain is significantly increased in individuals with Alzheimer's disease and that the ANKRIN protein is involved in the production of 尾-amyloid.

Ankyrin has also been shown to be involved in the development and progression of other neurodegenerative disorders, including Parkinson's disease and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and can be treated with neuroprotective drugs that aim to slow down or halt the progression of the disease.

In addition to its potential as a drug target and biomarker, ANKRIN also has potential as a therapeutic drug. The use of ANKRIN as a therapeutic drug is based on the idea that manipulating the activity of ANKRIN can have therapeutic effects on diseases that are caused by the disruption of normal cellular processes.

One of the most promising aspects of ANKRIN as a therapeutic drug is its potential to

Protein Name: Ankyrin Repeat Domain 62

The "ANKRD62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets